The conference theme “AIDS in Post 2015: Linking Leadership, Science & Human Rights” engages the whole continent and all stakeholders in the post MDG framework, where sustainability of the response in reaching 90, 90, 90 of UNAIDS will not be possible if Human rights are not key priority for a new vision of leadership in the context of strengthening the application of science based evidence.
The 18th ICASA is an opportunity to renew this global commitment by drawing the world’s attention to the fact that the legacy is now under threat as a result of the global economic downturn. This year’s ICASA is an opportunity for the international community, and all Africans, to join efforts in committing to achieving an AIDS-free Africa. Given the urgency of the issue we are anticipating 7 000 -10 000 of the world’s leading scientists, policy makers, activists, PLHIV, government leaders – as well as a number of heads of state and civil society representatives – will be joining the debate on how to achieve this vision.
The conference will be chaired by Dr Ihab AbdelRhaman Ahmed, an epidemiologist and President of the Society for AIDS in Africa (SAA). It will be co-chaired by Professor Mohamed Ridha Kamoun, a dermatologist and President of “Association Tunisienne de Luttecontre les MST et le SIDA’’.
The conference will be an excellent opportunity to promote inter-sectoral achievements in the AIDS response and to strengthen the partnership among governments, civil society, and development partners.
THE OBJECTIVES OF ICASA 2015:
- Increase African leadership and ownership, as well as investment in financing to support the continental health response.
- Strengthen the interaction between the public health, science and human right approaches in the control and elimination of the HIV/AIDS and associate diseases.
- Improve awareness and learning on knowledge, skills, best practices from the response to AIDS and other emergent epidemics (EBOLA, HEPATITIS, SRAS and NCD’s)
- Promote the development and scale up of evidence-based interventions for HIV/AIDS and associate diseases in the post 2015 era.